Methods, compositions, and kits for detecting and measuring endothelial injury in normal and diseased human central nervous system (cns)
AssigneeOhio State Innovation Foundation
InventorRawan TARAWNEH
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions useful in diagnosing, prognosing, monitoring, and treatment of neurological disorders. The markers are syndecan-1, syndecan-4, thrombomodulin, plasmalemmal vesicle-associated protein, E-selectin, and VE-cadherin. These markers can be used alone or in combination.
Claims27
A method for detecting endothelial injury in a subject and treating the subject accordingly, the method comprising detecting elevated levels of at least two of the following endothelial markers:
- syndecan-1, syndecan-4, thrombomodulin, plasmalemmal vesicle-associated protein, E-selectin, and VE-cadherin;
- and treating the subject accordingly.
(canceled)
(canceled)
(canceled)
A method of treating a neurodegenerative disorder in a subject, wherein the method comprises detecting elevated levels of at least two of the following endothelial markers:
- syndecan-1, syndecan-4, thrombomodulin, pl-VAP, E-selectin, and VE-cadherin;
- and treating the subject with elevated levels of two or more of these markers with treatments for a neurodegenerative disorder.
A method of monitoring effects of a composition on endothelial injury in a subject, the method comprising:
- a. measuring levels of at least two of the following endothelial markers in the subject:
- syndecan-1, syndecan-4, thrombomodulin, plasmalemmal vesicle-associated protein, E-selectin, and VE-cadherin;
- b. administering the composition to the subject;
- c. again measuring levels of at least two of the following endothelial markers in the subject:
- syndecan-1, syndecan-4, thrombomodulin, plasmalemmal vesicle-associated protein, E-selectin, and VE-cadherin;
- d. determining a significant change in the level of the markers from step a) to step c);
- and
- e. modifying an amount of the composition given, or discontinuing administration of the composition.
25-29. (canceled)
A kit comprising antibodies for detecting at least two of the following markers:
- syndecan-1, syndecan-4, thrombomodulin, plasmalemmal vesicle-associated protein, E-selectin, and VE-cadherin.
31-96. (canceled)
Dependencies are inferred from the claim text.